Finding ways to make brain tumors more responsive to radiation treatment
Official title: Exploiting cell fate transition to overcome radiation resistance in glioblastoma
Funded at New York University School of Medicine · NIH-10895462 · Data updated 2026-11-12
This study is looking at why some glioblastoma brain tumors don’t respond well to radiation therapy, and it aims to find new ways to make the treatment more effective by using special techniques to target the stubborn cells in the tumor.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 28, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $652,198 |
| NIH project number | 5R01CA282756-02 |
| Project ID | NIH-10895462 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with glioblastoma who are undergoing or have undergone radiation therapy.
✕Less likely to help
Patients with other types of brain tumors or those who are not receiving radiation therapy may not benefit from this research.
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor that is often resistant to radiation therapy. The team is investigating the molecular characteristics of glioblastoma stem-like cells to understand why some tumors resist treatment. By using advanced techniques like CRISPR gene editing, they aim to identify specific targets that can be manipulated to enhance the effectiveness of radiation therapy. The goal is to combine these new targets with standard radiation treatment to improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in targeting molecular pathways in glioblastoma, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Sulman, Erik — New York University School of Medicine
- Study coordinator: Sulman, Erik
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.